ETOHOPE FILM-COATED TABLET 60 mg

TABLET, FILM COATED

**Posology and method of administration** Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re - evaluated periodically, especially in patients with osteoarthritis. _Osteoarthritis_ In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _Rheumatoid arthritis_ The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _Ankylosing spondylitis_ The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _Acute pain conditions_ For acute pain conditions, etoricoxib should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. The recommended dose is 90mg or 120mg once daily. _Acute gouty arthritis_ The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days. Etoricoxib 120 mg should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. _Postoperative dental surgery pain_ The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to Etoricoxib Tablet during the three day treatment period. Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60 mg daily. The dose for RA and ankylosing spondylitis should not exceed 90 mg daily. The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment. The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days. Special populations _Elderly patients_ No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients. _Patients with hepatic impairment_ In patients with mild hepatic insufficiency (Child-Pugh score 5–6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic insufficiency (Child-Pugh score 7–9) the recommended dose of 60 mg _**every other day**_ should not be exceeded. Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score ≥10); therefore, its use is contra-indicated in these patients. _Patients with renal impairment_ No dosage adjustment is necessary for patients with creatinine clearance ≥30 ml/min. The use of etoricoxib in patients with creatinine clearance <30 ml/min is contra-indicated. _Paediatric population_ Etoricoxib is contra-indicated in children and adolescents under 16 years of age. Method of administration Etoricoxib Tablet is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when Etoricoxib Tablet is administered without food. This should be considered when rapid symptomatic relief is needed.